Good Therapeutics
About Good Therapeutics
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.
Company Metrics
- Employees: 1-10
- Monthly Visits: None
- Tech Stack: None active products
Financial Information
- Estimated Revenue: Less than $1M
- Total Funding: 30200000 USD
- Last Funding: 8000000 USD (Series B)
- Funding Status: M&A
Technology Stack
Good Therapeutics actively uses None products in their tech stack.
Market Presence
Industries: Biotechnology, Life Science, Pharmaceutical
Headquarters: Seattle, Washington, United States